Hjem › Ikke-småcellet lungekreft › Oklahoma › Oklahoma City
Kliniske studier for Ikke-småcellet lungekreft i Oklahoma City, OK
28 studier for Ikke-småcellet lungekreft søker deltakere på steder i og rundt Oklahoma City (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
RekruttererFase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekruttererFase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
- Integris Cancer Institute of Oklahoma, Oklahoma City
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekruttererFase 1/2
- University of Oklahoma, Oklahoma City
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RekruttererFase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
RekruttererFase 3
- Local Institution - 0418, Oklahoma City
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
RekruttererFase 3
- Hightower Clinical, LLC ( Site 0084), Oklahoma City
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
RekruttererFase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
RekruttererFase 2/3
- INTEGRIS Cancer Institute of Oklahoma, Oklahoma City
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RekruttererFase 1/2
- University of Oklahoma, Oklahoma City
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RekruttererFase 3
- Clinical Study Site, Oklahoma City
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
RekruttererFase 1/2
- OU Health Stephenson Cancer Center, Oklahoma City
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RekruttererFase 1
- OU Health Stephenson Cancer Center, Oklahoma City
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
RekruttererFase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekruttererFase 1/2
- University of Oklahoma - Health Sciences Center, Oklahoma City
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
RekruttererFase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RekruttererFase 1
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
- University of Oklahoma Health Science Center, Oklahoma City
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
RekruttererObservasjonsstudie
- Mercy Hospital - OKC, Oklahoma City
Study of XB010 in Subjects With Solid Tumors
RekruttererFase 1
- Stephenson Cancer Center, Oklahoma City
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
RekruttererFase 1
- OU Stephenson Cancer Center, Oklahoma City
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekruttererFase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
RekruttererFase 1/2
- Sarah Cannon Research Institute University of Oklahoma, Oklahoma City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2/3
- University of Oklahoma Health Sciences Center, Oklahoma City
- Integris Southwest Medical Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RekruttererObservasjonsstudie
- Mercy Hospital Oklahoma City, Oklahoma City
GEMINI-NSCLC: NSCLC Biomarker Study
RekruttererObservasjonsstudie
- Hightower Clinical, Oklahoma City
- Mercy Clinic Oncology and Hematology - Coletta, Oklahoma City
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
RekruttererFase 1
- Dren Investigational Site, Oklahoma City
A Study of NX-1607 in Adults With Advanced Malignancies
RekruttererFase 1
- University of Oklahoma, Oklahoma City
Ikke-småcellet lungekreft-studier i andre byer
- Houston, TX145 studier
- New York City, NY121 studier
- Arlington, VA104 studier
- Nashville, TN97 studier
- Boston, MA90 studier
- Los Angeles, CA87 studier
- St. Louis, MO73 studier
- Chicago, IL61 studier
- Baltimore, MD60 studier
- San Antonio, TX59 studier
- Columbus, OH57 studier
- Washington, DC55 studier
Andre studier i Oklahoma City
- Eggstokkreft28 studier
- Endometriekreft25 studier
- Kolorektal kreft22 studier
- Prostatakreft21 studier
- Lungekreft19 studier
- Brystkreft17 studier
- Metastatisk kreft16 studier
- Kreft (alle typer)14 studier
- Akut myelogen leukemi14 studier
- Plateepitelcancer i hode og hals13 studier
- Blærekreft11 studier
- Pankreaskreft11 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.